These findings underscore the potential of radiomics in predicting KRAS and BRAF mutations in CRC, providing crucial insights for personalized patient treatment and guiding future research toward enhancing model performance and validating the clinical utility of these biomarkers. Here, BRAF is linked to colorectal carcinoma.